1. DISEASE CHARACTERISTICS 1.1 Name of the disease (synonyms) Dyskeratosis congenita (Zinsser-Engman-Cole Syndrome). 1-11
OMIM# of the disease Three modes of inheritance:
X-linked recessive (OMIM #305000)
Autosomal dominant (OMIM #127550) Autosomal recessive (OMIM #224230)
1.3 Name of the analysed genes or DNA/chromosome segments DKC1 X-linked recessive (B25% of DC)
TERC

Autosomal dominant (B5% of DC) TERT
Autosomal dominant and autosomal recessive (B5% of DC)
NOP10
Autosomal recessive (o1% of DC)
NHP2
TINF2
Autosomal dominant (B12% of DC) USB1
Autosomal recessive (B2% of DC)
TCAB1
Autosomal recessive (o1% of DC) CTC1
Autosomal recessive (B1% of DC)
RTEL1
Autosomal recessive (B2% of DC) TERC, TERT, NOP10, NHP2, TINF2 , USB1, TCAB1, CTC1 and RTEL1) followed by denaturing, HPLC and/or direct DNA sequence analysis.
OMIM# of the gene(s)
DKC1
Analytical validation
Sequencing of the appropriate DNA fragment.
1.8 Estimated frequency of the disease (Incidence at birth ('birth prevalence') or population prevalence): 1 in 1 000 000 (approximate).
1.9 If applicable, prevalence in the ethnic group of investigated person 1 in 1 000 000 (approximate). NB: It is noteworthy 'classical DC' often presents as a multisystem disorder in the paediatric age group, whereas adult patients presenting with one or more feature of DC display a very variable phenotype and the associated telomerase mutations are usually acting as risk factors. DC and related disorders thus represent a very wide clinical and genetic spectrum. 
Diagnostic setting
TEST CHARACTERISTICS
Negative value:
2.1 Analytical sensitivity (proportion of positive tests if the genotype is present) Not determined; probably 495%.
Analytical specificity (proportion of negative tests if the genotype is not present)
Difficult to comment on as the genetic basis is currently only known for approximately 60% of DC patients.
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.
As features of the disease develop progressively with time individuals with pathogenic variants may not have any/all clinical features at the time of analysis. The age of onset and range of clinical features is very variable.
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.
As the genetic diagnosis can only be substantiated in about 60% of cases at present, not finding a variant in 1 of the 10 known DC genes does not definitively exclude the diagnosis of DC.
Positive clinical predictive value (life time risk to develop the disease if the test is positive)
This is high (490%) for DKC1 and TINF2 variants, but difficult to be precise for TERC and TERT variants, as variants in these genes have a variable penetrance, and are sometimes seen as risk factors for the development of disease.
Negative clinical predictive value (probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested: Index case in that family had not been tested: As highlighted previously, since the genetic basis is only known in about 60% of DC cases not finding a variant in 1 of the 10 known DC genes does not exclude the possibility of developing DC. It is also important to note that some mutations (particularly in the TERT gene) are not associated with disease in all individuals carrying the variant; suggesting that the variant is more a risk factor for the development of disease. In patients with classical features (eg, presence of mucocutaneous triad), clinical diagnosis is possible. However as there is considerable variant in the onset and severity of clinical features, diagnosis exclusively based on clinical features is both difficult and unreliable. This is further highlighted by some of the 'cryptic' presentations of DC (eg, aplastic anaemia); in such cases it is the finding of a pathogenic variant in one of the DC genes that helps in clinching the diagnosis of DC.
How is the cost effectiveness of alternative diagnostic methods to be judged?
Clinical diagnosis is dependent on clinical expertise. A delay in diagnosis can lead to inappropriate and inadequate management. This may, in some cases, lead to increased morbidity and mortality.
Flow-FISH and Q-FISH measurement of leucocyte telomere length are currently only available as a diagnostic method in a few labs and are relatively expensive. Telomere length measurement should perhaps be regarded as a good screening test for DC. Individuals found to have very short telomeres (o1st centile) should ideally go on to have genetic analysis for the DC genes.
Will disease management be influenced by the result of a genetic test?
No & Yes 2
Therapy (please describe)
This is complicated. For the haematological defect (which is a major cause of mortality) patients with DC are more likely to respond to androgens (eg, oxymetholone or danazol) rather than to the conventional immunosuppressive (antithymocyte globulin and cyclosporine) therapy used in idiopathic aplastic anaemia. The diagnosis of DC will also influence the details of patient monitoring. It will also influence the drug conditioning regimen (low intensity) in patients who become candidates for BM transplantation.
Prognosis (please describe)
This can vary considerably from death in infancy (usually due to bone marrow failure or immune deficiency) to that in the seventh decade. The major causes of death relate to BM failure (B70%), cancer (B10%) and lung disease (pulmonary interstitial disease, B10-20%). The BM failure develops progressively with time; up to 80% of patients will have BM failure by the age of 30 years. Cancer (haematological and nonhaematological) usually develops after the third decade. The most frequent solid malignancies are head and neck squamous cell carcinomas.
Management (please describe)
As this is a multisystem disorder it is important to monitor many systems of the body.
BM failure is one of the commonest and severe complications. About 50-70% of patients will respond to androgens, but patients have to be monitored carefully for side effects. For those who do not have an efficacious response to androgens and have a compatible BM donor, haemopoietic stem cell transplantation using a low-intensity conditioning regime is an option. It is important to use low-intensity conditioning regimes as conventional regimes using radiotherapy or busulphan are associated with high toxicity and poor survival.
Treatment for cancer depends on the specific cancer but consideration has to be given to the underlying DC (ie, more supportive care, reduce drug doses). With regards to pulmonary disease, patients should be encouraged to avoid smoking. Medical treatment is usually difficult in severe lung disease; lung transplant may be an option in some cases. Advice on skin care (eg, use of moisturising creams) and avoidance of sunlight is important. Liver disease (cirrhosis and noncirrhotic portal hypertension) is more common in DC patients than the normal population. Alcohol consumption should therefore be kept to a minimum and all drug administrations require close monitoring.
Predictive setting:
The tested person is clinically unaffected but carries an increased risk based on family history (To be answered if in 1.10 'B' was marked)
Will the result of a genetic test influence lifestyle and prevention?
If the test result is positive (please describe):
The management plan will have an impact on lifestyle. As highlighted above it is important that patients with DC (or predicted to be at risk of developing DC based on genetic testing) avoid smoking, sunlight, and keep alcohol intake to a minimum. They should also avoid occupations that expose them to hazardous chemicals.
If the test result is negative (please describe): No specific lifestyle change necessary. 
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe) In female carriers of X-linked DC (DKC1), there is usually no medical problem. However, X-linked DC carriers can go onto give rise to affected boys. Carrier testing for the X-linked gene (DKC1) in appropriate families is therefore useful even though usually it has no immediate clinical consequences for the carrier.
